Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 22876 AL 22890

Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies

Puranik N, Kumari M, Tiwari S, Dhakal T, Song M.

Nutrients. 2025 Aug 5;17(15):2557. doi: 10.3390/nu17152557.

A Narrative Review on the Neuroprotective Effects of Selenium and Vitamin D in Alzheimer's Disease

Bragais EK, Luna KLD, Timoteo-Garcia VJ.

Biol Trace Elem Res. 2026 Mar;204(3):1848-1865. doi: 10.1007/s12011-025-04788-7. Epub 2025 Aug 14.

Revisiting APOE: Insights from rare variants and the expanding landscape of Alzheimer's disease genetics

Gim J.

J Alzheimers Dis. 2025 Oct;107(4):1409-1410. doi: 10.1177/13872877251366662. Epub 2025 Aug 17.

Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co-pathologies, and sex differences

Shwab EK, Pathak GA, Harvey J, Belloy ME, Fischer CE, Lutz MW, Scholz SW, Cook N, Reid DM, Chen J, Guan DX, Oliveira F, Sinclair LI, Imo U, Creese B, Chiba-Falek O; Neuropsychiatric Syndromes Professional Interest Area Multiomics Work Group, Alzheimer's Association, International Society to Advance Alzheimer's Research and Treatment, Chicago, Illinois, USA.

Alzheimers Dement. 2025 Aug;21(8):e70549. doi: 10.1002/alz.70549.

[Donanemab, an Amyloid β-targeting Antibody for Early Symptomatic Alzheimer's Disease: Summary of Clinical Study Results]

Sato S, Iwata A, Ishii K, Kamiki E, Nishimoto T.

Brain Nerve. 2025 Aug;77(8):907-920. doi: 10.11477/mf.188160960770080907.

APOE4 reprograms microglial lipid metabolism in Alzheimer's disease: Mechanisms and therapeutic implications

Chen J, Zhao S, Zhou Y, Wang L, Chen Q, Zheng K.

Biosci Trends. 2026 Jan 7;19(6):641-658. doi: 10.5582/bst.2025.01148. Epub 2025 Aug 21.

[The mechanism of PI3K/AKT pathway in Alzheimer's disease and the research progress of acupuncture intervention]

Chen YZ, Wei YT, Xiao M, Xie WT, Yan XK.

Zhen Ci Yan Jiu. 2025 Aug 25;50(8):965-973. doi: 10.13702/j.1000-0607.20240371.

Bioenergetic failure and oxidative stress: mitochondrial contributions to Alzheimer's disease

Wasim R.

Inflammopharmacology. 2025 Sep;33(9):5273-5289. doi: 10.1007/s10787-025-01916-6. Epub 2025 Aug 27.

Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease

Koga-Batko J, Antosz-Popiołek K, Nowakowska H, Błażejewska M, Kowalik EM, Beszłej JA, Leszek J.

Int J Mol Sci. 2025 Aug 10;26(16):7725. doi: 10.3390/ijms26167725.

Honey as a Neuroprotective Agent: Molecular Perspectives on Its Role in Alzheimer's Disease

Navarro-Hortal MD, Romero-Márquez JM, Ansary J, Hinojosa-Nogueira D, Montalbán-Hernández C, Varela-López A, Quiles JL.

Nutrients. 2025 Aug 8;17(16):2577. doi: 10.3390/nu17162577.

Unravelling neuronal death mechanisms: The role of cytokines and chemokines in immune imbalance in Alzheimer's disease progression

Kumari S, Dhapola R, Sharma P, Paidlewar M, Vellingiri B, Medhi B, HariKrishnaReddy D.

Ageing Res Rev. 2025 Dec;112:102883. doi: 10.1016/j.arr.2025.102883. Epub 2025 Aug 28.

[Insulin signaling and neuropathological changes in Alzheimer's disease]

Wakabayashi T.

Nihon Yakurigaku Zasshi. 2025;160(5):324-328. doi: 10.1254/fpj.25019.

The Therapeutic Potential of Flavonols in Alzheimer's Disease: Inhibiting Amyloid-β, Oxidative Stress, and Neuroinflammation

Zamanian MY, Khachatryan LG, Heidari M, Darabi R, Golmohammadi M, Al-Aouadi RFA, Akkol EK.

Biofactors. 2025 Sep-Oct;51(5):e70047. doi: 10.1002/biof.70047.

Harnessing nanoparticles for Alzheimer's disease: Innovations in drug delivery and pathology-specific treatments

Liu G, Sun Y.

J Alzheimers Dis. 2025 Oct;107(4):1374-1399. doi: 10.1177/13872877251374149. Epub 2025 Sep 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias